The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee
entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
This study will test the effects and safety of stopping inhaled hypertonic saline or dornase alfa (Pulmozyme®) in teens and adults with CF who are also taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (Trikafta®). Trikafta® is intended to help CFTR function closer to normal, resulting in better clearance of mucus from the lungs. Inhaled hypertonic saline and dornase alfa are intended to thin airway surface liquid and improve clearance of mucus from the lungs. They are considered to be relatively burdensome therapies, so this study will look at the impact of stopping them in people who are also taking Trikafta®.
Age:
12 Years and Older
Mutation(s):
No Mutation Requirement
FEV1% Predicted:
60% or greater
Number of Visits:
4
Length of Participation:
10 weeks
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
